Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Bachert (Ghent, Belgium), R. Naclerio (Chicago, United States of America), P. Hellings (Leuven, Belgium), S. Guillonneau (Chilly-Mazarin, France), C. Taniou (Nanterre, France), J. Maroni (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), L. Mannent (Chilly-Mazarin, France), N. Amin (Tarrytown, United States of America), S. Kamat (Tarrytown, United States of America), A. Khan (Chilly-Mazarin, France). Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP). 5004

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma Source: International Congress 2017 – Management of asthma in different situations Year: 2017 Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Effect of FESS on asthma patients with nasal polyposis and chronic sinusitis Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016 Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Aspirin-induced urticaria/angioedema without respiratory symptoms in severe asthmatics with nasal polyposis Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002 The clinical relationship of nasal polyposis to asthma and other pathologies in the French population Source: Eur Respir J 2003; 22: Suppl. 45, 114s Year: 2003 Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 Incidence of nasal polyposis and its association with the development of chronic bronchitis and/or emphysema Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019